Eluvia Drug-Eluting Vascular Stent

 

Ranger Paclitaxel-Coated PTA Balloon Catheter

Resources › Data Sheets :

Data Sheets

IMPERIAL Data Sheet

View the remarkable results Eluvia achieved in the first head-to-head trial: Eluvia DES vs. Zilver PTX.

Download the Data Sheet ›

2-year results from IMPERIAL

Evaluate the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.

Download the Data Sheet ›

RANGER II SFA Pivotal Trial Data Sheet

See the 12-month full cohort results of the Ranger II SFA Pivotal Trial.

Download the Data Sheet ›

COMPARE Clinical Data Sheet

Learn more about the world’s first head-to-head, prospective, multi-center Randomized Controlled Trial (1:1) comparing the lower dose Paclitaxel RANGER DCB (2 µg/mm2) to the higher dose Paclitaxel IN.PACT DCB (3.5 µg/mm2).

Download the Data Sheet ›

1. Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

2. Versus 87.0% primary patency in the none/mild calcium arm of the IMPERIAL Calcium Subgroup.